These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 26255760

  • 21. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug.
    Bourdage JS, Cook CA, Farrington DL, Chain JS, Konrad RJ.
    J Immunol Methods; 2007 Oct 31; 327(1-2):10-7. PubMed ID: 17716682
    [Abstract] [Full Text] [Related]

  • 22. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
    Xiang Y, Parng C, Olson K, Seletskaia E, Gorovits B, Jani D, Caiazzo T, Joyce A, Donley J.
    AAPS J; 2019 Mar 29; 21(3):46. PubMed ID: 30927117
    [Abstract] [Full Text] [Related]

  • 23. A biotin-drug extraction and acid dissociation (BEAD) procedure to eliminate matrix and drug interference in a protein complex anti-drug antibody (ADA) isotype specific assay.
    Niu H, Klem T, Yang J, Qiu Y, Pan L.
    J Immunol Methods; 2017 Jul 29; 446():30-36. PubMed ID: 28389174
    [Abstract] [Full Text] [Related]

  • 24. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
    Harth S, Frisch C.
    Methods Mol Biol; 2021 Jul 29; 2261():291-306. PubMed ID: 33420997
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody.
    Liao K, Meyer E, Lee TN, Loercher A, Sikkema D.
    J Immunol Methods; 2017 Feb 29; 441():15-23. PubMed ID: 27889561
    [Abstract] [Full Text] [Related]

  • 26. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
    Wessels U, Schick E, Ritter M, Kowalewsky F, Heinrich J, Stubenrauch K.
    Bioanalysis; 2017 Jun 29; 9(11):849-859. PubMed ID: 28517957
    [Abstract] [Full Text] [Related]

  • 27. Drug interference in immunogenicity assays depends on valency.
    Rispens T, Hart MH, Ooijevaar-de Heer P, van Leeuwen A, Vennegoor A, Killestein J, Wolbink GJ, van der Kleij D.
    J Pharm Biomed Anal; 2013 Nov 29; 85():179-85. PubMed ID: 23954437
    [Abstract] [Full Text] [Related]

  • 28. Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity.
    Dai S, Schantz A, Clements-Egan A, Cannon M, Shankar G.
    AAPS J; 2014 May 29; 16(3):464-77. PubMed ID: 24590506
    [Abstract] [Full Text] [Related]

  • 29. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays.
    Dengler AF, Weiss R, Truong T, Irvin SC, Gadhia N, Hassanein M, Georgaros C, Taylor JA, Paccaly A, Sumner G, Andisik MD, Torri A, Partridge MA.
    AAPS J; 2021 Oct 04; 23(6):109. PubMed ID: 34608545
    [Abstract] [Full Text] [Related]

  • 30. Quantification of a bifunctional drug in the presence of an immune response: a ligand-binding assay specific for 'active' drug.
    Staack RF, Jordan G, Viert M, Schäfer M, Papadimitriou A, Heinrich J.
    Bioanalysis; 2015 Dec 04; 7(24):3097-106. PubMed ID: 26484402
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
    Kharlamova N, Hermanrud C, Dunn N, Ryner M, Hambardzumyan K, Vivar Pomiano N, Marits P, Gjertsson I, Saevarsdottir S, Pullerits R, Fogdell-Hahn A.
    Front Immunol; 2020 Dec 04; 11():1365. PubMed ID: 32793189
    [Abstract] [Full Text] [Related]

  • 33. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
    Xu W, Jiang H, Titsch C, Haulenbeek JR, Pillutla RC, Aubry AF, DeSilva BS, Arnold ME, Zeng J, Dodge RW.
    J Immunol Methods; 2015 Jan 04; 416():94-104. PubMed ID: 25445325
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Collaborative study using common samples to evaluate the performance of anti-drug antibody assays constructed by different companies.
    Niimi S, Nishimiya K, Nishidate M, Saito T, Minoura K, Kadotsuji K, Shimakura J, Shigemizu H, Hosogi J, Adachi M, Hashimoto T, Mori T, Harada H, Yamamoto KI, Nakamura T, Nomura T, Yamaguchi I, Sonehara K, Ishii-Watabe A, Kawasaki N.
    Drug Metab Pharmacokinet; 2018 Apr 04; 33(2):125-132. PubMed ID: 29610053
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies.
    Chen YQ, Pottanat TG, Carter QL, Troutt JS, Konrad RJ, Sloan JH.
    J Immunol Methods; 2016 Apr 04; 431():45-51. PubMed ID: 26874304
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.